BR112014021653A2 - Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica - Google Patents

Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica

Info

Publication number
BR112014021653A2
BR112014021653A2 BR112014021653A BR112014021653A BR112014021653A2 BR 112014021653 A2 BR112014021653 A2 BR 112014021653A2 BR 112014021653 A BR112014021653 A BR 112014021653A BR 112014021653 A BR112014021653 A BR 112014021653A BR 112014021653 A2 BR112014021653 A2 BR 112014021653A2
Authority
BR
Brazil
Prior art keywords
topical formulation
formulation
topical
manufacture
wound treatment
Prior art date
Application number
BR112014021653A
Other languages
English (en)
Other versions
BR112014021653B1 (pt
Inventor
Gautam Ghatnekar
Original Assignee
Firststring Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Firststring Res Inc filed Critical Firststring Res Inc
Publication of BR112014021653A2 publication Critical patent/BR112014021653A2/pt
Publication of BR112014021653B1 publication Critical patent/BR112014021653B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica. a invenção se refere à preparação medicamentosa de um gel tópico que contém uma composição compreendendo um polipeptídeo isolado com uma sequência de aminoácido de carboxilo terminal de alfaconexina (act peptídico ), estabilizadores de peptídeo, excipientes, agentes de tamponamento e similares. as etapas de formulação e preparação são apresentadas na fabricação de um gel tópico estável, apurado e fluídico. a formulação decorrente apresenta uma longa estabilidade e é apropriada a aplicações estéticas e terapêuticas, incluindo a prevenção de cicatrizes, e à cicatrização rápida de feridas.
BR112014021653-3A 2012-03-01 2013-03-01 Formulação tópica, uso da formulação tópica e método para fabricar uma formulação tópica BR112014021653B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605528P 2012-03-01 2012-03-01
US61/605,528 2012-03-01
PCT/US2013/028727 WO2013131040A1 (en) 2012-03-01 2013-03-01 Topical gels containing alpha connexin c-terminal (act) peptides

Publications (2)

Publication Number Publication Date
BR112014021653A2 true BR112014021653A2 (pt) 2022-05-10
BR112014021653B1 BR112014021653B1 (pt) 2023-03-28

Family

ID=49083360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014021653-3A BR112014021653B1 (pt) 2012-03-01 2013-03-01 Formulação tópica, uso da formulação tópica e método para fabricar uma formulação tópica

Country Status (18)

Country Link
US (5) US8846605B2 (pt)
EP (1) EP2819682B1 (pt)
JP (1) JP6185937B2 (pt)
KR (1) KR102038948B1 (pt)
CN (1) CN104271142B (pt)
AU (1) AU2013225716B2 (pt)
BR (1) BR112014021653B1 (pt)
CA (1) CA2866115C (pt)
DK (1) DK2819682T3 (pt)
HK (1) HK1205451A1 (pt)
IL (1) IL234380B (pt)
IN (1) IN2014DN07420A (pt)
MX (1) MX351881B (pt)
NZ (1) NZ629769A (pt)
RU (1) RU2657535C2 (pt)
SG (1) SG11201405359YA (pt)
WO (1) WO2013131040A1 (pt)
ZA (1) ZA201406373B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2684150C (en) 2007-05-14 2016-10-04 Research Foundation Of State University Of New York Decenoic acid dispersion inducers in the treatment of biofilms
WO2013131040A1 (en) 2012-03-01 2013-09-06 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides
US11246821B2 (en) * 2016-08-30 2022-02-15 Rohm And Haas Company Personal care composition
MX2019009753A (es) * 2017-02-16 2019-12-18 Firststring Res Inc Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos.
US20210137809A1 (en) * 2017-06-14 2021-05-13 Biosolution Co., Ltd Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR20210057072A (ko) * 2018-09-12 2021-05-20 퍼스트스트링 리서치 인코포레이티드 알파 코넥신 c-말단 펩타이드에 대한 나노 입자 제제 및 사용 방법
RU2691647C1 (ru) * 2018-11-29 2019-06-17 Артем Иванович Трофименко Средство для профилактики образования патологических кожных рубцов
US11751056B2 (en) * 2020-08-31 2023-09-05 Oracle International Corporation Methods, systems, and computer readable media for 5G user equipment (UE) historical mobility tracking and security screening using mobility patterns
WO2023212446A1 (en) * 2022-04-29 2023-11-02 Xequel Bio, Inc. Compositions and methods for treating complications of viral infections and other respiratory disorders
CN117582401B (zh) * 2023-12-07 2024-04-26 唐宁医药科技(济南)有限公司 一种糖尿病足凝胶及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3603444A1 (de) * 1986-02-05 1987-08-06 Thomae Gmbh Dr K Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
NZ222413A (en) 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
US5401504B1 (en) * 1993-12-28 1998-04-21 Univ Mississippi Medical Cente Use of tumeric in wound healing
AU776512B2 (en) 1999-01-27 2004-09-09 David Laurence Becker Formulations comprising antisense nucleotides to connexins
WO2000069896A2 (en) 1999-05-14 2000-11-23 Arbor Vita Corporation Molecular interactions in haematopoietic cells
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
AU2002239336A1 (en) 2000-11-10 2002-06-03 Arbor Vita Corporation Molecular interactions in hematopoietic cells
WO2002088370A2 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Autogene nucleic acids encoding a secretable rna polymerase
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US6685971B2 (en) 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
CN1827766B (zh) 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
AU2002321903A1 (en) 2001-08-03 2003-02-24 Arbor Vita Corporation Molecular interactions in cells
CA2461542A1 (en) 2001-10-17 2003-04-24 Tudor Morley Griffith Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
JP2003238441A (ja) 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
WO2003096981A2 (en) 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
KR101359741B1 (ko) 2003-12-03 2014-02-06 코다 테라퓨틱스, 인크. 코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
WO2006069181A2 (en) * 2004-12-21 2006-06-29 Musc Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
CN101151043B (zh) * 2004-12-21 2013-09-04 南卡罗来纳州医科大学研究发展基金会 促进伤口愈合和组织再生的组合物和方法
EP1959981B1 (en) 2005-02-03 2019-10-16 Coda Therapeutics Limited Anti-connexin 43 compounds for treating chronic wounds
CN101198345A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 用于治疗或阻止组织衰退、损伤或损害的lkktet和/或lkktnt组合物及方法
JP2008543877A (ja) * 2005-06-17 2008-12-04 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法
WO2007044487A1 (en) * 2005-10-11 2007-04-19 Dfb Pharmaceuticals, Inc. Surfactant-free dispersions, compositions, and use in topical formulations
GB0709513D0 (en) * 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations
EP2091557A2 (en) 2006-11-15 2009-08-26 Coda Therapeutics, INC. Improved methods and compositions for wound healing
PT2101791E (pt) 2006-12-11 2014-12-18 Coda Therapeutics Inc Polinucleótidos anti-conexina como composições para cicatrização dificultada de feridas
US20080299228A1 (en) * 2007-05-29 2008-12-04 Alan Gerald Harris Topical compositions comprising a macromolecule and methods of using same
EP2166845B1 (en) 2007-06-21 2015-10-21 Musc Foundation for Research Development Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration
CA2592285C (en) 2007-06-28 2019-10-01 Musc Foundation For Research Development Compositions comprising connexin polypeptides and methods for promoting wound healing and tissue regeneration using connexin polypeptides
JP2011506447A (ja) 2007-12-11 2011-03-03 コーダ セラピューティクス， インコーポレイテッド 損傷した創傷治癒組成物および治療
US20110300130A1 (en) * 2007-12-11 2011-12-08 Becker David L Impaired wound healing compositions and treatments
US20110130710A1 (en) 2007-12-21 2011-06-02 David Lawrence Becker Treatment of abnormal or excessive scars
CA2710232A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
EP2234656A2 (en) * 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
EP2242844A2 (en) 2007-12-21 2010-10-27 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
AU2008343839A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
WO2009085270A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions
JP2011507856A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 整形外科状態の治療のための抗コネキシンポリヌクレオチド、ペプチド、または抗体の使用
CA2710387A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of fibrotic conditions
US20110144182A1 (en) 2007-12-21 2011-06-16 David Lawrence Becker Treatment of surgical adhesions
WO2009097077A2 (en) * 2008-01-07 2009-08-06 Coda Therapeutics, Inc. Wound healing compositions and treatments
CA2727015A1 (en) 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
WO2013131040A1 (en) 2012-03-01 2013-09-06 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides

Also Published As

Publication number Publication date
RU2657535C2 (ru) 2018-06-14
US20210128682A1 (en) 2021-05-06
EP2819682A1 (en) 2015-01-07
IN2014DN07420A (pt) 2015-04-24
CA2866115A1 (en) 2013-09-06
CA2866115C (en) 2020-03-24
US9161984B2 (en) 2015-10-20
NZ629769A (en) 2016-09-30
EP2819682A4 (en) 2016-01-06
US10632173B2 (en) 2020-04-28
DK2819682T3 (en) 2017-08-21
SG11201405359YA (en) 2014-09-26
BR112014021653B1 (pt) 2023-03-28
US8846605B2 (en) 2014-09-30
KR102038948B1 (ko) 2019-11-26
RU2014139668A (ru) 2016-04-20
US20230263857A1 (en) 2023-08-24
CN104271142B (zh) 2017-07-04
US20150018284A1 (en) 2015-01-15
US20160058834A1 (en) 2016-03-03
JP6185937B2 (ja) 2017-08-23
KR20140132388A (ko) 2014-11-17
IL234380B (en) 2020-10-29
MX351881B (es) 2017-11-01
WO2013131040A1 (en) 2013-09-06
AU2013225716A1 (en) 2014-09-18
JP2015513549A (ja) 2015-05-14
CN104271142A (zh) 2015-01-07
EP2819682B1 (en) 2017-05-03
MX2014010501A (es) 2015-03-09
HK1205451A1 (en) 2015-12-18
US11524049B2 (en) 2022-12-13
ZA201406373B (en) 2015-12-23
US20130267471A1 (en) 2013-10-10
AU2013225716B2 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
BR112014021653A2 (pt) Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2013013913A (es) Polipeptidos.
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112015001782A2 (pt) método para produzir uma composição para o tratamento de um dente lesionado
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
MX340985B (es) Compuestos de n-heteroarilo.
UY33334A (es) Proteina de fusion Robol-Fc y su utilizacion en el tratamiento de tumores .
BR112015019412A2 (pt) inibidores de bace1
WO2014141210A3 (en) Multifunctional immature dental pulp stem cells and therapeutic applications
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
BR112013026698A2 (pt) formulações do tipo tópica compreendendo depsipeptídeo cíclico
AR112474A1 (es) Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
BRPI1006076B8 (pt) composições farmacêuticas
MX360726B (es) Péptidos del veneno de escorpión rhopalurus junceus y composición farmacéutica.
BR112016005899A2 (pt) composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano
BR112015014367A2 (pt) formulações inibidoras de lfa-1
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação

Legal Events

Date Code Title Description
B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/03/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.